HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Pharmagel, Updates Webpage On Drug-Claim Violations

This article was originally published in The Rose Sheet

Executive Summary

Pharmagel's name and billing as "pharmaceutical grade anti-aging skin care" may have drawn FDA's attention, but benefits cited in the agency's warning letter – including collagen- and elastic-building claims – are consistent with FDA's enforcement action against other companies so far in 2015.

You may also be interested in...



FDA Warning Letter Recipients: Where Are Their Claims Now?

A key component of FDA’s enforcement strategy in the cosmetics space is monitoring companies’ websites for overreaching product claims and issuing warning letters accordingly. Examination of past offenders’ current sites and updated claims offers potential visibility into language the agency will and will not tolerate when it comes to promoting skin-care benefits.

House Cosmetics Bill Seeks Broad Federal Preemption, Revised 'Cosmetic' Definition

A bill introduced in the House Nov. 18 would preempt state regulations governing safe cosmetic ingredient use and health-related labeling requirements, such as those under California's Prop 65 law, and revise the "cosmetic" definition under federal law to allow for limited use of structure/function claims.

FDA's Final IND Guidance Has Industry On Edge: What Happens Next?

It remains to be seen how industry responds to FDA's newly reissued final guidance advising firms to file Investigational New Drug applications for studies exploring would-be cosmetics' structure/function benefits, and how rigorously the agency enforces its position. Attorney Paul Hyman speculates that FDA could rely on INDs to reinforce its authority in the context of warning letters issued to cosmetics firms for unapproved drug claims.

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel